Rapt Therapeutics Inc.
RAPT Therapeutics Announces Positive Phase 2 Trial Results for RPT904 in Chronic Spontaneous Urticaria
Summary
On October 20, 2025, RAPT Therapeutics, Inc. and Shanghai Jeyou Pharmaceutical Co., Ltd. announced positive topline data from Jeyou's phase 2 trial of RPT904 (JYB1904) in chronic spontaneous urticaria (CSU). The trial showed that RPT904 dosed at 8-week and 12-week intervals had comparable efficacy and safety to omalizumab dosed every 4 weeks. The data indicate that RPT904 has potential for more convenient dosing and improved compliance, which could lead to better clinical outcomes. The results support advancing RPT904 to phase 3 development and warrant discussions with regulatory authorities. Additionally, RAPT plans to initiate a phase 2b clinical trial of RPT904 in food allergies before the end of 2025.
Profitelligence Alerts
Get alerts for RAPT
Be first to know when Rapt Therapeutics Inc. files with the SEC.
Filing Categories
Advertisement
About Rapt Therapeutics Inc.
Rapt Therapeutics Inc. is a biotechnology firm focused on the discovery, development, and commercialization of oral small molecule therapies for oncology and inflammatory diseases. Its primary mission is to create novel treatments by harnessing its proprietary drug discovery platform, which targets key pathways responsible for the progression of these complex conditions. Rapt Therapeutics is notably advancing its development of selective inhibitors for immune checkpoint inhibitors within the broader cancer treatment landscape, potentially enhancing the efficacy of existing therapies. The company's pipeline includes multiple drug candidates tailored for specific types of cancer and chronic inflammatory disorders, underscoring its commitment to addressing unmet medical needs. By concentrating efforts on innovative approaches that modulate immune and inflammatory responses, Rapt Therapeutics plays a significant role in shaping the future of precision medicine in the biopharmaceutical industry. Founded in 2015 and leveraging advanced scientific insights, Rapt Therapeutics represents an important component of the biotech sector's efforts to push boundaries in disease treatment and improve patient outcomes.
Official SEC Documents
Advertisement